Heidelberg Pharma AG

HPHA

Equity

ISIN DE000A11QVV0 / Valor 24937540

Xetra (2024-11-22)

EUR 2.23+2.76%

Heidelberg Pharma AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Heidelberg Pharma AG, originally founded as Wilex Biotechnology GmbH in September 1997 and later renamed, is a biopharmaceutical company headquartered in Ladenburg, Germany. The company specializes in the field of oncology, with a particular focus on the development of Antibody Drug Conjugates (ADCs) aimed at treating various cancers. Heidelberg Pharma has pioneered the use of Amanitin-based ADCs, known as ATACs, leveraging the toxin's novel mechanism of action for therapeutic purposes. Its proprietary ATAC platform underpins both its own drug development pipeline and partnerships with third parties to generate a range of ATAC candidates. Among its leading development projects are HDP-101, a BCMA-ATAC targeting multiple myeloma, HDP-102 for Non-Hodgkin lymphoma, and HDP-103, aimed at addressing metastatic castration-resistant prostate cancer. The company's innovative approach to cancer treatment positions it as a notable player in the oncology sector, with its shares traded on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-20.6%1Y

-61.7%3Y

4.69%5Y

Performance

42.4%1Y

53.5%3Y

69.6%5Y

Volatility